Last update 28 May 2025

Lenvatinib mesylate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
lenvatinib, lenvatinib mesilate, Lenvatinib mesilate (JAN)
+ [18]
Action
antagonists, inhibitors
Mechanism
FGFR1 antagonists(Fibroblast growth factor receptor 1 antagonists), FGFR2 antagonists(Fibroblast growth factor receptor 2 antagonists), FGFR3 antagonists(Fibroblast growth factor receptor 3 antagonists)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
United States (13 Feb 2015),
RegulationBreakthrough Therapy (United States), Accelerated Approval (United States), Orphan Drug (United States), Priority Review (China), Conditional marketing approval (China), Special Review Project (China), Orphan Drug (Japan), Orphan Drug (Australia), Priority Review (Australia)
Login to view timeline

Structure/Sequence

Molecular FormulaC22H23ClN4O7S
InChIKeyHWLFIUUAYLEFCT-UHFFFAOYSA-N
CAS Registry857890-39-2

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Advanced Endometrial Carcinoma
European Union
25 Jul 2023
Advanced Endometrial Carcinoma
Iceland
25 Jul 2023
Advanced Endometrial Carcinoma
Liechtenstein
25 Jul 2023
Advanced Endometrial Carcinoma
Norway
25 Jul 2023
Recurrent Endometrial Cancer
European Union
25 Jul 2023
Recurrent Endometrial Cancer
Iceland
25 Jul 2023
Recurrent Endometrial Cancer
Liechtenstein
25 Jul 2023
Recurrent Endometrial Cancer
Norway
25 Jul 2023
Thymus Neoplasms
Japan
23 Mar 2021
Advanced Renal Cell Carcinoma
European Union
25 Aug 2016
Advanced Renal Cell Carcinoma
Iceland
25 Aug 2016
Advanced Renal Cell Carcinoma
Liechtenstein
25 Aug 2016
Advanced Renal Cell Carcinoma
Norway
25 Aug 2016
Endometrial Carcinoma
Australia
28 Jan 2016
Renal Cell Carcinoma
Australia
28 Jan 2016
Advanced Hepatocellular Carcinoma
European Union
28 May 2015
Advanced Hepatocellular Carcinoma
Iceland
28 May 2015
Advanced Hepatocellular Carcinoma
Liechtenstein
28 May 2015
Advanced Hepatocellular Carcinoma
Norway
28 May 2015
Differentiated Thyroid Gland Carcinoma
European Union
28 May 2015
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Lung Non-Small Cell CarcinomaPhase 3
China
28 Oct 2021
Metastatic Esophageal CarcinomaPhase 3
United States
28 Jul 2021
Metastatic Esophageal CarcinomaPhase 3
United States
28 Jul 2021
Metastatic Esophageal CarcinomaPhase 3
China
28 Jul 2021
Metastatic Esophageal CarcinomaPhase 3
China
28 Jul 2021
Metastatic Esophageal CarcinomaPhase 3
Japan
28 Jul 2021
Metastatic Esophageal CarcinomaPhase 3
Japan
28 Jul 2021
Metastatic Esophageal CarcinomaPhase 3
Argentina
28 Jul 2021
Metastatic Esophageal CarcinomaPhase 3
Argentina
28 Jul 2021
Metastatic Esophageal CarcinomaPhase 3
Canada
28 Jul 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
297
Lenvatinib + TACE
gmpxgnmomc(cdnrxznibh) = pxtjcvnuhh krmjerszqu (lsaxifaswx )
Positive
01 Jun 2025
gmpxgnmomc(cdnrxznibh) = oqpzibbryt krmjerszqu (lsaxifaswx )
Phase 1/2
-
Lenvatinib 11 mg/m2 + Everolimus 3 mg/m2
biksxnnaft(fzspmofncl) = lixjhbapcp uhfzlfoukx (kmnzhpbzra )
Positive
01 May 2025
Lenvatinib 8 mg/m2 + Everolimus 3 mg/m2
biksxnnaft(fzspmofncl) = fgkszqdfsy uhfzlfoukx (kmnzhpbzra )
Not Applicable
-
-
bzdlmcaatm(rsfkkuinim) = beuntfzyet oldcjjmedm (hhifzdugka )
Positive
27 Apr 2025
Phase 2
29
masfhlvvdv = luzisnqlwe wqqkhhyngi (vgddikibbk, whmyemzkws - olmkmvjcjb)
-
16 Apr 2025
Phase 2
43
hoyokwayqw(hcoyldogbz) = maxpftgxym yvkfpgfuwg (gkdpmderry )
Positive
26 Mar 2025
wgbbbdpene(okpdipflfx) = wmktuddtjn edwgqkoqpk (gtjzhvhckc )
Phase 2
11
Research blood collection+pembrolizumab+Lenvatinib
xdyauiefqx = ujljyzzupm wkyszchche (angnaivisc, thrpcycdzb - qsczfhrfoz)
-
21 Mar 2025
Not Applicable
371
Lenvatinib + anti-PD-1/L1 + interventional therapy
bcfmqzwlmg(fuofkjpcwk) = both groups had similar rates of serious adverse events (P = 0.895) cuqpndeqif (ifcypwtryz )
Positive
03 Mar 2025
Phase 3
761
(Part 1 First Course: Pembrolizumab+Chemotherapy+Lenvatinib)
cpbqsatzap = cuonprsypc zmypyndcmg (mortrzwwyo, qnjrcihbnz - uzuvvxvbnx)
-
21 Feb 2025
(Part 2 First Course: Pembrolizumab+Chemotherapy+Lenvatinib)
gvbwppijdd(qhodgjjmmb) = wdrpulqwnc agtsspgvhe (xmxgdffjuu, feuspkenld - lhkhqmtjxv)
Phase 1/2
Liver Cancer
Second line | Third line
-
cysvaueaxd(mpjbfdduqr) = mjnmntkdiy wnofvqbscn (xjlzdyhdvi, 7.6 – NR)
Positive
20 Feb 2025
Not Applicable
64
pinaahmhvb(hyefousjqm) = foetclkodv jjyvroqfuz (goevbnndxb )
Positive
20 Feb 2025
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free